Characteristics of the 834 patients undergoing nonmyeloablative conditioning
| Parameter . | Value . |
|---|---|
| Median age, y (range) | 55 (5-74) |
| Sex, n | |
| Male | 537 |
| Female | 297 |
| Hematopoietic graft, n | |
| G-PBMC | 816 |
| Marrow | 18 |
| Diagnosis, n | |
| Multiple myeloma | 165 |
| AML | 152 |
| NHL | 146 |
| MDS | 103 |
| CLL | 82 |
| Hodgkin lymphoma | 51 |
| CML | 47 |
| ALL | 30 |
| Myeloproliferative disease | 19 |
| Renal-cell carcinoma | 18 |
| CMML | 12 |
| Waldenström disease | 9 |
| No. of preceding chemotherapy regimens, median (range) | 3 (0-19) |
| Preceding autologous HCT, no. patients | |
| No | 510 |
| Yes* | 324 |
| Conditioning regimens, n | |
| 2 Gy TBI | 171 |
| 2 Gy TBI + fludarabine | 663 |
| Donor, n | |
| Related | 498 |
| Unrelated | 336 |
| Median duration of follow-up†, mo (range) | 37.1 (2.8-98.7) |
| Parameter . | Value . |
|---|---|
| Median age, y (range) | 55 (5-74) |
| Sex, n | |
| Male | 537 |
| Female | 297 |
| Hematopoietic graft, n | |
| G-PBMC | 816 |
| Marrow | 18 |
| Diagnosis, n | |
| Multiple myeloma | 165 |
| AML | 152 |
| NHL | 146 |
| MDS | 103 |
| CLL | 82 |
| Hodgkin lymphoma | 51 |
| CML | 47 |
| ALL | 30 |
| Myeloproliferative disease | 19 |
| Renal-cell carcinoma | 18 |
| CMML | 12 |
| Waldenström disease | 9 |
| No. of preceding chemotherapy regimens, median (range) | 3 (0-19) |
| Preceding autologous HCT, no. patients | |
| No | 510 |
| Yes* | 324 |
| Conditioning regimens, n | |
| 2 Gy TBI | 171 |
| 2 Gy TBI + fludarabine | 663 |
| Donor, n | |
| Related | 498 |
| Unrelated | 336 |
| Median duration of follow-up†, mo (range) | 37.1 (2.8-98.7) |
TBI indicates total body irradiation; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndromes; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; CMML, chronic myelomonocytic leukemia; CR, complete remission; PR, partial remission; HCT, hematopoietic cell transplantation; G-PBMC, granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells.
Planned, n = 148; failed, n = 176; 121 patients with MM had planned autologous HCT (8 of these had failed another preceding autologous HCT) and an additional 29 had failed autologous HCT.
Follow-up duration for 390 surviving patients.